Business Context and Reporting Period
Syndax Pharmaceuticals, Inc. (SNDX) filed this Form 8-K on December 22, 2021, to report the entry into a material definitive agreement. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Debt Structure
This filing details an amendment to the Company's Loan and Security Agreement rather than reporting operational financial results such as revenue or profit.
- Total Borrowing Capacity: Increased from $30.0 million to $80.0 million.
- Outstanding Borrowings: $20.0 million (Tranche 1 drawn on February 7, 2020).
- Tranche 2 Availability: Increased to $30.0 million total. $15.0 million available at the Company's option through April 30, 2022; an additional $15.0 million available through November 30, 2022 (extendable to April 30, 2023 if the first portion is drawn).
- Tranche 3 Availability: New tranche of $30.0 million available subject to the Agent's investment committee approval through the Interest-Only Period.
- Interest Rate: Reduced to the greater of 9.25% or 6.00% plus the Wall Street Journal prime rate (previously the greater of 9.85% or 5.10% plus prime).
- Interest-Only Period: Extended to January 1, 2023, with an option to extend to December 31, 2023 upon partial or full draw of Tranche 2.
- Maturity Date: Extended from September 1, 2023, to April 1, 2024.
- Fees: 0.50% facility charge on future draws; 4.99% end-of-term charge on future draws payable at maturity.
Material Changes Versus Prior Period
The First Amendment significantly altered the terms of the Existing Loan Agreement dated February 7, 2020:
- Capacity Increase: Borrowing limit increased by $50.0 million.
- Cost Reduction: Annual interest rate floor decreased from 9.85% to 9.25%.
- Liquidity Extension: Maturity date extended by approximately 7 months; interest-only period extended by approximately 15 months.
- Covenants: Added a minimum cash covenant applicable upon the occurrence of certain events and permitted the entry into a Collaboration and License Agreement with Incyte Corporation.
- Prepayment Premiums: Reset to 2.0% (Year 1), 1.5% (Year 2), and 1.0% (thereafter) of the principal amount outstanding.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding future operational performance. The primary focus is on the restructuring of debt facilities to support future liquidity needs.
Risks and Contingencies:
- Availability of Tranche 3 is subject to the Agent's investment committee approval.
- Extension of the interest-only period to December 31, 2023, is contingent upon the partial or full draw of Tranche 2.
- The Company is subject to a new minimum cash covenant upon the occurrence of certain events.
Important Facts for Investor Verification
- Verify the exact terms of the minimum cash covenant and the specific events that trigger its applicability.
- Confirm the status of the Collaboration and License Agreement with Incyte Corporation referenced in the amendment.
- Monitor the Company's cash burn rate to assess the likelihood of drawing Tranche 2 and Tranche 3 within the specified availability windows.
- Note that the filing states the full text of the First Amendment will be filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 2021.